Celcuity (CELC) is trading lower in a modest pullback, a move that fits a profit-taking pattern after a strong biotech run driven by regulatory momentum in gedatolisib. The company’s most recent high-impact catalyst remains the FDA’s acceptance of its gedatolisib NDA with Priority Review and a PDUFA goal date of July 17, 2026—news that lifted expectations for a potential U.S. approval decision this summer.

In its March 25, 2026 corporate update alongside full-year 2025 results, Celcuity reiterated that topline results from the PIK3CA-mutant cohort of its Phase 3 VIKTORIA-1 trial are expected in Q2 2026. With that readout still pending and no fresh clinical data released today, the stock’s dip looks tied more to positioning and valuation sensitivity than to a new negative fundamental development.

Near-term sentiment is likely to stay anchored to two dates: (1) the expected Q2 2026 VIKTORIA-1 PIK3CA-mutant topline readout, which could expand the commercial opportunity if positive, and (2) the July 17, 2026 PDUFA goal date for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer. Any shifts in either timeline—or incremental details on labeling, safety, or launch readiness—could quickly change the tape.

Celcuity reported cash, cash equivalents, and short-term investments of $441.5 million at year-end 2025 and said it expects that to finance operations through 2027. That runway can help support ongoing trials and commercial launch preparation, but the stock can still be volatile as investors re-price the probability and timing of approval and commercialization.